Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anagrelide - Takeda

Drug Profile

Anagrelide - Takeda

Alternative Names: Agrelid; Agrelin; Agrylin; Anagrelide hydrochloride; BL 4162A; BMY 2653801; KRN654; SPD422; Xagrid

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Takeda
  • Class 3-ring heterocyclic compounds; Antiplatelets; Antithrombotics; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Fibrinolytic agents; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytosis

Most Recent Events

  • 10 Apr 2019 Shire completes a phase I pharmacokinetics trial in healthy volunteers in USA (PO, Capsule) (NCT03866434)
  • 11 Mar 2019 NCT03866434: Added FET; CTP not created yet; brief review done
  • 07 Mar 2019 Shire plans a phase I pharmacokinetics trial in healthy volunteers in USA (PO, Capsule) (NCT03866434)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top